1. Home
  2. TENX vs VIVO Comparison

TENX vs VIVO Comparison

Compare TENX & VIVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

N/A

Current Price

$2.13

Market Cap

71.1M

Sector

Health Care

ML Signal

N/A

Logo VivoPower PLC Ordinary Shares

VIVO

VivoPower PLC Ordinary Shares

N/A

Current Price

$4.06

Market Cap

80.1M

Sector

Utilities

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
VIVO
Founded
1967
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Power Generation
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
71.1M
80.1M
IPO Year
2001
2016

Fundamental Metrics

Financial Performance
Metric
TENX
VIVO
Price
$2.13
$4.06
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$29.67
N/A
AVG Volume (30 Days)
9.0M
468.7K
Earning Date
05-15-2026
05-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$1.97
52 Week High
$19.40
$6.86

Technical Indicators

Market Signals
Indicator
TENX
VIVO
Relative Strength Index (RSI) 23.92 51.62
Support Level $1.31 $4.20
Resistance Level $14.15 $5.20
Average True Range (ATR) 0.20 0.30
MACD 0.17 0.01
Stochastic Oscillator 75.00 34.15

Price Performance

Historical Comparison
TENX
VIVO

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About VIVO VivoPower PLC Ordinary Shares

VivoPower PLC is engaged in building, owning, and leasing powered land and data center infrastructure for AI compute applications. The group delivers specialized infrastructure solutions across the AI Data Centers, Power-to-X, and Electric Mobility. It is develop and operated infrastructure that enables sovereign nations and institutional partners to secure control over power, data, and national intelligence, supporting AI, compute-intensive workloads, and energy transition use cases.

Share on Social Networks: